These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 18166178)
1. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Reh A; Oktem O; Oktay K Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178 [TBL] [Abstract][Full Text] [Related]
2. Ovarian function and childbearing issues in breast cancer survivors. Gadducci A; Cosio S; Genazzani AR Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162 [TBL] [Abstract][Full Text] [Related]
3. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543 [TBL] [Abstract][Full Text] [Related]
4. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy]. Yasumura T; Oka T; Honjo H; Okada H Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733 [TBL] [Abstract][Full Text] [Related]
5. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291 [TBL] [Abstract][Full Text] [Related]
6. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients]. Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008 [TBL] [Abstract][Full Text] [Related]
7. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460 [TBL] [Abstract][Full Text] [Related]
8. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. Petrek JA; Naughton MJ; Case LD; Paskett ED; Naftalis EZ; Singletary SE; Sukumvanich P J Clin Oncol; 2006 Mar; 24(7):1045-51. PubMed ID: 16476708 [TBL] [Abstract][Full Text] [Related]
9. GnRH analogue for chemotherapy-induced ovarian damage: too early to say? Peccatori F; Demeestere I Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600 [No Abstract] [Full Text] [Related]
10. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay. Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363 [TBL] [Abstract][Full Text] [Related]
11. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S; J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042 [TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Badawy A; Elnashar A; El-Ashry M; Shahat M Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959 [TBL] [Abstract][Full Text] [Related]
13. [Breast cancer and fertility: critical review, considerations and perspectives]. This P Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566 [TBL] [Abstract][Full Text] [Related]
14. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Fornier MN; Modi S; Panageas KS; Norton L; Hudis C Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178 [TBL] [Abstract][Full Text] [Related]
15. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093 [TBL] [Abstract][Full Text] [Related]
16. Measuring the impact of chemotherapy on fertility in women with breast cancer. Oktay K; Oktem O; Reh A; Vahdat L J Clin Oncol; 2006 Aug; 24(24):4044-6. PubMed ID: 16921067 [No Abstract] [Full Text] [Related]
17. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603 [TBL] [Abstract][Full Text] [Related]
18. [Effect of chemotherapy to ovary function in ovarian malignancy patients undergoing conservative surgery]. Sun ZY; Shen K; Lang JH; Huang HF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):431-3. PubMed ID: 12974089 [TBL] [Abstract][Full Text] [Related]
19. Estrogen deficiency and bone loss in women with breast cancer. Shapiro CL Breast Cancer Res Treat; 2010 Oct; 123(3):815-8. PubMed ID: 20697804 [No Abstract] [Full Text] [Related]
20. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Davis AL; Klitus M; Mintzer DM Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]